Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Infection Prevention and Control
How do you make decisions about decolonization for a chronic asymptomatic MRSA carrier?
Related Questions
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
For which pediatric oncology patients do you start bacterial prophylaxis, inpatient or outpatient, and what is your antibiotic of choice?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
What are your top takeaways from ID Week 2024?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How do you decide on supportive care vs empiric antibiotics in a patient with suspected aspiration pneumonitis (i.e., witnessed macroaspiration event within the past 24 hours) but with features that could suggest pneumonia (e.g., acute respiratory distress, fever, leukocytosis, pulmonary infiltrates, etc.)?
How would you approach treatment duration for patients with persistent Candida species fungemia with a history of a prosthetic heart valve but negative TEE/CT PET and no other identifiable source of infection?
Have you ever seen a case of C. difficile from topical mupiricin?
Do you routinely prescribe linezolid to patients who are concomitantly on methadone?
